{"entity":{"id":"nct03852511","kind":"trial","name":"First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)","aka":[],"tldr":"A phase 1 trial of NG-350A run by Akamis Bio, completed.","summary":"First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) is a phase 1 interventional study registered as NCT03852511 by Akamis Bio, with 28 participants enrolled, started 2019-02-19, primary completion reached 2022-02-04. Conditions recorded: Metastatic Cancer, Epithelial Tumor. Interventions recorded: NG-350A.","status":"completed","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT03852511","url":"https://clinicaltrials.gov/study/NCT03852511"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["ng-350a"],"companies":["akamis-bio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03852511","phase":"1","setting":"A Multicentre, Open Label, Non-randomised First in Human Study of NG-350A (Monotherapy), and NG-350A With a Check Point Inhibitor in Patients With Metastatic or Advanced Epithelial Tumours","sponsor":"Akamis Bio","enrolled":28,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03852511/","neighbours":{"drug":[{"id":"ng-350a","kind":"drug","name":"NG-350A","route":"/drugs/ng-350a/"}],"company":[{"id":"akamis-bio","kind":"company","name":"Akamis Bio","route":"/companies/akamis-bio/"}]}}